Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Englander Institute for Precision Medicine
Englander Institute for Precision Medicine
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
Partnerships
Career Opportunities
Publications
Toggle Publications menu options
A Modified Mediterranean Ketogenic Diet mitigates modifiable risk factors of Alzheimer's Disease: a serum and CSF-based metabolic analysis.
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.
A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.
A deep learning pipeline for automated classification of vocal fold polyps in flexible laryngoscopy.
A guideline on the molecular ecosystem regulating ferroptosis.
A mitochondrial checkpoint to adaptive anticancer immunity.
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
A reversible epigenetic memory of inflammatory injury controls lineage plasticity and tumor initiation in the mouse pancreas.
A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.
Adaptive inhibition of CGAS signaling by TREX1.
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.
Ariadne: synthetic long read deconvolution using assembly graphs.
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.
Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.
Bacterial antigens unleash tumor-targeting immunity.
Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.
Cancer stem cell immunoediting by IFNγ.
Cell death and senescence.
Cellular senescence and aging at the crossroad between immunity and cancer.
ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.
Chromosomal instability drives immunosuppression and metastatic dissemination.
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy.
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.
Correction: Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.
Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.
Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis.
Dual impact of radiation therapy on tumor-targeting immune responses.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Elevated A-to-I RNA editing in COVID-19 infected individuals.
Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
Epigenetic memory of coronavirus infection in innate immune cells and their progenitors.
Epinephrine inhibits PI3Kα via the Hippo kinases.
Evolution of structural rearrangements in prostate cancer intracranial metastases.
FORMATION OF MALIGNANT, METASTATIC SMALL CELL LUNG CANCERS THROUGH OVERPRODUCTION OF cMYC PROTEIN IN TP53 AND RB1 DEPLETED PULMONARY NEUROENDOCRINE CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS.
Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions.
Genomic sequence context differs between germline and somatic structural variants allowing for their differentiation in tumor samples without paired normals.
Immunogenicity of ferroptosis in cancer: a matter of context?
Immunological aspects of central neurodegeneration.
Immunosurveillance in clinical cancer management.
Immunotherapy in the Treatment of Localized Genitourinary Cancers.
Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
Interferon signaling restrains renal cell carcinoma heterogeneity.
International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis.
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.
Male infertility.
Mapping human natural killer cell development in pediatric tonsil by imaging mass cytometry and high-resolution microscopy.
Metabolomics profiling reveals distinct, sex-specific signatures in the serum and brain metabolomes in the mouse models of Alzheimer's disease.
Mitochondrial control of antigen presentation in cancer cells.
Molecular determinants of immunogenic cell death elicited by radiation therapy.
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types.
NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis.
NIPBL::NACC1 Fusion Hepatic Carcinoma.
Nanoparticle enrichment mass-spectrometry proteomics identifies protein-altering variants for precise pQTL mapping.
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Non-mutational neoantigens in disease.
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
Pan-cancer proteogenomics characterization of tumor immunity.
Pan-cancer proteogenomics connects oncogenic drivers to functional states.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Radiation therapy: An old dog learning new tricks.
Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Recapitulation of patient-specific 3D chromatin conformation using machine learning.
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
SPRY4-dependent ERK negative feedback demarcates functional adult stem cells in the male mouse germline†.
Senolytic treatment reduces oxidative protein stress in an aging male murine model of post-traumatic osteoarthritis.
TIMP1 is an early biomarker for detection and prognosis of lung cancer.
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer.
The synthetic phospholipid C8-C1P determines pro-angiogenic and pro-reparative features in human macrophages restraining the proinflammatory M1-like phenotype.
Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.
Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women.
Type I interferon and cancer.
USING MACHINE LEARNING METHODS TO ASSESS THE RISK OF ALCOHOL MISUSE IN OLDER ADULTS.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Voice as an AI Biomarker of Health-Introducing Audiomics.
Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.
Whole-genome Analysis Elucidates Complex Genomic Events in GLI1 -rearranged Enteric Tumor.
cloudrnaSPAdes: Isoform assembly using bulk barcoded RNA sequencing data.
cloudrnaSPAdes: isoform assembly using bulk barcoded RNA sequencing data.
miR-218 Promotes Dopaminergic Differentiation and Controls Neuron Excitability and Neurotransmitter Release through the Regulation of a Synaptic-Related Genes Network.
Donate
Contact Us
Patient Care
Toggle Patient Care menu options
For Patients
For Clinicians
Precision Medicine Studies
Research
Toggle Research menu options
Clinical Research
Toggle Clinical Research menu options
Research Enrollment and Biobanking
Clinical Data Management
Research Laboratory
Toggle Research Laboratory menu options
Next Generation Sequencing
Precision Pathology
Cutting Edge Technology
Toggle Cutting Edge Technology menu options
Mass Cytometry
Spatial Profiling
Preclinical Models & Drug Screens
Toggle Preclinical Models & Drug Screens menu options
Organoid Platform
High-Throughput Drug Screening & Preclinical Pharmacy
Computational Biology & Informatics
AI-XR Lab
Fusion Projects
Education
Toggle Education menu options
Faculty, Fellows & Residents
Students
Learning Resources
News & Events
Toggle News & Events menu options
EIPM Researcher Receives Grant for Blood Test to Diagnose Breast Cancer
Events
Toggle Events menu options
EIPM Seminar Series | The application of spatial biology for the characterization of Crohn's disease
Precision Medicine Conference | Whole Genome Sequencing of Ovarian Cancer
Town Hall | Englander Institute for Precision Medicine
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Patient Care
Research
Education
News & Events
Home
About Us
Publications
Our Team
Partnerships
Career Opportunities
Publications
Donate
Contact Us
Explore
A Modified Mediterranean Ketogenic Diet mitigates modif(...)
A Pilot Study on Hyperthermic Intraperitoneal Chemother(...)
A biologic-device combination product delivering tumor-(...)
A combinatorial genetic strategy for exploring complex (...)
A deep learning pipeline for automated classification o(...)
A guideline on the molecular ecosystem regulating ferro(...)
A mitochondrial checkpoint to adaptive anticancer immunity.
A pancreatic cancer organoid platform identifies an inh(...)
A reversible epigenetic memory of inflammatory injury c(...)
A signature of enhanced proliferation associated with r(...)
Adaptive inhibition of CGAS signaling by TREX1.
Anti-EGFR Antibodies in the Management of Advanced Colo(...)
Ariadne: synthetic long read deconvolution using assemb(...)
Author Correction: Evolution of structural rearrangemen(...)
Author Correction: Genetic features and therapeutic rel(...)
Author Correction: Neoadjuvant durvalumab plus radiatio(...)
Avelumab First-line Maintenance for Advanced Urothelial(...)
Avelumab first-line maintenance treatment for advanced (...)
BCL2 Inhibition Reveals a Dendritic Cell-Specific Immun(...)
Bacterial antigens unleash tumor-targeting immunity.
Bone-matrix mineralization dampens integrin-mediated me(...)
Cancer stem cell immunoediting by IFNγ.
Cell death and senescence.
Cellular senescence and aging at the crossroad between (...)
ChromaFold predicts the 3D contact map from single-cell(...)
Chromosomal instability drives immunosuppression and me(...)
Circulating Tumor DNA Enables Sensitive Detection of Ac(...)
Co-occurring BRCA2/SPOP Mutations Predict Exceptional P(...)
Comparative brain metabolomics reveals shared and disti(...)
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splic(...)
Correction: Metasurface-enhanced infrared spectroscopy (...)
Cysteine induces mitochondrial reductive stress in glio(...)
Deciphering the origin and therapeutic targets of cance(...)
Dual impact of radiation therapy on tumor-targeting imm(...)
Efficacy and Safety of Darolutamide in Combination With(...)
Elevated A-to-I RNA editing in COVID-19 infected indivi(...)
Endoglin, a Novel Biomarker and Therapeutical Target to(...)
Epigenetic memory of coronavirus infection in innate im(...)
Epinephrine inhibits PI3Kα via the Hippo kinases.
Evolution of structural rearrangements in prostate canc(...)
FORMATION OF MALIGNANT, METASTATIC SMALL CELL LUNG CANC(...)
Genetic associations with ratios between protein levels(...)
Genomic sequence context differs between germline and s(...)
Immunogenicity of ferroptosis in cancer: a matter of co(...)
Immunological aspects of central neurodegeneration.
Immunosurveillance in clinical cancer management.
Immunotherapy in the Treatment of Localized Genitourina(...)
Individual bioenergetic capacity as a potential source (...)
Insulin feedback is a targetable resistance mechanism o(...)
Interferon signaling restrains renal cell carcinoma het(...)
International consensus guidelines for the definition, (...)
Long-molecule scars of backup DNA repair in BRCA1- and (...)
Male infertility.
Mapping human natural killer cell development in pediat(...)
Metabolomics profiling reveals distinct, sex-specific s(...)
Mitochondrial control of antigen presentation in cancer(...)
Molecular determinants of immunogenic cell death elicit(...)
Molecular features of prostate cancer after neoadjuvant(...)
Multiscale protein networks systematically identify abe(...)
NAK-associated protein 1/NAP1 activates TBK1 to ensure (...)
NIPBL::NACC1 Fusion Hepatic Carcinoma.
Nanoparticle enrichment mass-spectrometry proteomics id(...)
Neoadjuvant durvalumab plus radiation versus durvalumab(...)
Non-mutational neoantigens in disease.
Noninvasive Detection of Neuroendocrine Prostate Cancer(...)
Outcomes of relapsed clinical stage I versus de novo me(...)
Pan-cancer proteogenomics characterization of tumor imm(...)
Pan-cancer proteogenomics connects oncogenic drivers to(...)
Patient-derived tumor organoids with p53 mutations, and(...)
Patient-derived tumor organoids with p53 mutations, and(...)
Plain language summary: Can declines in prostate-specif(...)
Plasma metabolomics profiling of 580 patients from an E(...)
Prognostic value of neutrophil-to-lymphocyte ratio in p(...)
Radiation therapy: An old dog learning new tricks.
Radiopharmaceuticals as combinatorial partners for immu(...)
Randomized phase II trial of MRI-guided salvage radioth(...)
Recapitulation of patient-specific 3D chromatin conform(...)
SPOP Mutations Target STING1 Signaling in Prostate Canc(...)
SPRY4-dependent ERK negative feedback demarcates functi(...)
Senolytic treatment reduces oxidative protein stress in(...)
TIMP1 is an early biomarker for detection and prognosis(...)
The Identification of CELSR3 and Other Potential Cell S(...)
The Landscape of US and Global Rare Tumor Research Prog(...)
The importance of escalating molecular diagnostics in p(...)
The synthetic phospholipid C8-C1P determines pro-angiog(...)
Transcriptomic signatures of chronic active antibody-me(...)
Tumor-Associated Lymphocytes and Breast Cancer Survival(...)
Type I interferon and cancer.
USING MACHINE LEARNING METHODS TO ASSESS THE RISK OF AL(...)
Updates on radiotherapy-immunotherapy combinations: Pro(...)
Voice as an AI Biomarker of Health-Introducing Audiomics.
Whole-Genome Sequencing Analysis of Male Breast Cancer (...)
Whole-genome Analysis Elucidates Complex Genomic Events(...)
cloudrnaSPAdes: Isoform assembly using bulk barcoded RN(...)
cloudrnaSPAdes: isoform assembly using bulk barcoded RN(...)
miR-218 Promotes Dopaminergic Differentiation and Contr(...)
Publications
Found 22 results
Author
Title
Type
[
Year
]
Filters:
Author
is
Tombal, Bertrand
[Clear All Filters]
2024
Shore ND
,
Hussain M
,
Saad F
,
Fizazi K
,
Sternberg CN
,
Crawford D
,
Tombal B
,
Nordquist L
,
Cookson M
,
Verholen F
et al.
. 2024.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
.
Oncologist. 29(3):235-243.
2023
Higano CS
,
George DJ
,
Shore ND
,
Sartor O
,
Miller K
,
Conti PS
,
Sternberg CN
,
Saad F
,
Sade JPablo
,
Bellmunt J
et al.
. 2023.
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.
.
EClinicalMedicine. 60:101993.
Hussain M
,
Tombal B
,
Saad F
,
Fizazi K
,
Sternberg CN
,
E Crawford D
,
Shore N
,
Kopyltsov E
,
Kalebasty ARezazadeh
,
Bögemann M
et al.
. 2023.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
.
J Clin Oncol. 41(20):3595-3607.
Gillessen S
,
Bossi A
,
Davis ID
,
de Bono J
,
Fizazi K
,
James ND
,
Mottet N
,
Shore N
,
Small E
,
Smith M
et al.
. 2023.
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
.
Eur Urol. 83(3):267-293.
Gillessen S
,
Bossi A
,
Davis ID
,
de Bono J
,
Fizazi K
,
James ND
,
Mottet N
,
Shore N
,
Small E
,
Smith M
et al.
. 2023.
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
.
Eur J Cancer. 185:178-215.
2022
Smith MR
,
Hussain M
,
Saad F
,
Fizazi K
,
Sternberg CN
,
Crawford D
,
Manarite J
,
Muslin D
,
Farrington T
,
Tombal B
. 2022.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
.
Future Oncol. 18(21):2585-2597.
Smith MR
,
Hussain M
,
Saad F
,
Fizazi K
,
Sternberg CN
,
E Crawford D
,
Kopyltsov E
,
Park CH
,
Alekseev B
,
Montesa-Pino Á
et al.
. 2022.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
.
N Engl J Med. 386(12):1132-1142.
Gillessen S
,
Armstrong A
,
Attard G
,
Beer TM
,
Beltran H
,
Bjartell A
,
Bossi A
,
Briganti A
,
Bristow RG
,
Bulbul M
et al.
. 2022.
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
.
Eur Urol. 82(1):115-141.
Sartor O
,
George D
,
Tombal B
,
Agarwal N
,
Higano CS
,
Sternberg CN
,
Miller K
,
Jiao XL
,
Guo H
,
Sandström P
et al.
. 2022.
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
.
Future Oncol. 18(1):35-45.
George DJ
,
Agarwal N
,
Sartor O
,
Sternberg CN
,
Tombal B
,
Saad F
,
Miller K
,
Constantinovici N
,
Guo H
,
Reeves J
et al.
. 2022.
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
.
Prostate Cancer Prostatic Dis. 25(2):306-313.
Joshua AM
,
Armstrong A
,
Crumbaker M
,
Scher HI
,
de Bono J
,
Tombal B
,
Hussain M
,
Sternberg CN
,
Gillessen S
,
Carles J
et al.
. 2022.
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
.
Eur J Cancer. 170:285-295.
Turco F
,
Armstrong A
,
Attard G
,
Beer TM
,
Beltran H
,
Bjartell A
,
Bossi A
,
Briganti A
,
Bristow RG
,
Bulbul M
et al.
. 2022.
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
.
Eur Urol. 82(1):6-11.
De Giorgi U
,
Hussain M
,
Shore N
,
Fizazi K
,
Tombal B
,
Penson D
,
Saad F
,
Efstathiou E
,
Madziarska K
,
Steinberg J
et al.
. 2022.
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Future Oncol. 18(35):3867-3874.
2021
Suzuki H
,
Castellano D
,
de Bono J
,
Sternberg CN
,
Fizazi K
,
Tombal B
,
Wülfing C
,
Foster MC
,
Ozatilgan A
,
Geffriaud-Ricouard C
et al.
. 2021.
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
.
Jpn J Clin Oncol. 51(8):1287-1297.
De Giorgi U
,
Hussain M
,
Shore N
,
Fizazi K
,
Tombal B
,
Penson D
,
Saad F
,
Efstathiou E
,
Madziarska K
,
Steinberg J
et al.
. 2021.
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
.
Eur J Cancer. 159:237-246.
Sternberg CN
,
Castellano D
,
de Bono J
,
Fizazi K
,
Tombal B
,
Wülfing C
,
Kramer G
,
Eymard J-C
,
Bamias A
,
Carles J
et al.
. 2021.
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
.
Eur Urol. 80(4):497-506.
Tombal B
,
Stenzl A
,
Cella D
,
Loriot Y
,
Armstrong AJ
,
Fizazi K
,
Beer T
,
Sternberg CN
,
Hussain M
,
Ivanescu C
et al.
. 2021.
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.
.
Cancers (Basel). 13(23)
2020
Armstrong AJ
,
Al-Adhami M
,
Lin P
,
Parli T
,
Sugg J
,
Steinberg J
,
Tombal B
,
Sternberg CN
,
de Bono J
,
Scher HI
et al.
. 2020.
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
.
JAMA Oncol. 6(2):217-225.
Gillessen S
,
Attard G
,
Beer TM
,
Beltran H
,
Bjartell A
,
Bossi A
,
Briganti A
,
Bristow RG
,
Chi KN
,
Clarke N
et al.
. 2020.
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
.
Eur Urol. 77(4):508-547.
Fizazi K
,
Kramer G
,
Eymard J-C
,
Sternberg CN
,
de Bono J
,
Castellano D
,
Tombal B
,
Wülfing C
,
Liontos M
,
Carles J
et al.
. 2020.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
.
Lancet Oncol. 21(11):1513-1525.
2019
de Wit R
,
de Bono J
,
Sternberg CN
,
Fizazi K
,
Tombal B
,
Wülfing C
,
Kramer G
,
Eymard J-C
,
Bamias A
,
Carles J
et al.
. 2019.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
.
N Engl J Med. 381(26):2506-2518.
Jayaram A
,
Wingate A
,
Wetterskog D
,
Conteduca V
,
Khalaf D
,
Sharabiani MTaghavi Az
,
Calabrò F
,
Barwell L
,
Feyerabend S
,
Grande E
et al.
. 2019.
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.
.
JCO Precis Oncol. 3
]